Prevexxion RN RSS Authorised This medicine is authorised for use in the European Union Marek's disease vaccine (live recombinant) Medicine Veterinary Authorised
Page contentsPage contents Overview Product information Product details Authorisation details Assessment history News on Prevexxion RN Topics Application under evaluation CVMP opinion European Commission decision OverviewUp-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website Prevexxion RN : EPAR - Medicine overviewReference Number: EMA/321108/2020 English (EN) (81.94 KB - PDF)First published: 16/04/2021 Last updated: 14/03/2025 View Other languages (25) български (BG) (93.36 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View español (ES) (81.97 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View čeština (CS) (93.99 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View dansk (DA) (83.34 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Deutsch (DE) (82.76 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View eesti keel (ET) (82.18 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View ελληνικά (EL) (93.76 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View français (FR) (82.44 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View hrvatski (HR) (92.27 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View íslenska (IS) (83.29 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Gaeilge (GA) (83.57 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View italiano (IT) (82.29 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View latviešu valoda (LV) (94.29 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View lietuvių kalba (LT) (94.03 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View magyar (HU) (94.15 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Malti (MT) (95.95 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Nederlands (NL) (82.05 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View norsk (NO) (82 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View polski (PL) (95.62 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View português (PT) (83.01 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View română (RO) (94.17 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View slovenčina (SK) (94.08 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View slovenščina (SL) (82.27 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Suomi (FI) (81.54 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View svenska (SV) (82.05 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Product information Prevexxion RN : EPAR - Product information English (EN) (81.49 KB - PDF)First published: 16/04/2021 Last updated: 14/03/2025 View Other languages (25) български (BG) (91.78 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View español (ES) (81.51 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View čeština (CS) (92.48 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View dansk (DA) (82.05 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Deutsch (DE) (81.72 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View eesti keel (ET) (81.22 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View ελληνικά (EL) (91.79 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View français (FR) (81.63 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View hrvatski (HR) (91.56 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View íslenska (IS) (81.52 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Gaeilge (GA) (81.36 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View italiano (IT) (81.76 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View latviešu valoda (LV) (92.14 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View lietuvių kalba (LT) (92.19 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View magyar (HU) (92.76 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Malti (MT) (93.86 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Nederlands (NL) (81.15 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View norsk (NO) (81.52 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View polski (PL) (93.22 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View português (PT) (82.53 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View română (RO) (91.73 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View slovenčina (SK) (81.75 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View slovenščina (SL) (81.76 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Suomi (FI) (81.11 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View svenska (SV) (81.47 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Prevexxion RN : EPAR - All authorised presentations English (EN) (81.94 KB - PDF)First published: 16/04/2021 Last updated: 14/03/2025 View Other languages (25) български (BG) (93.36 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View español (ES) (81.97 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View čeština (CS) (93.99 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View dansk (DA) (83.34 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Deutsch (DE) (82.76 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View eesti keel (ET) (82.18 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View ελληνικά (EL) (93.76 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View français (FR) (82.44 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View hrvatski (HR) (92.27 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View íslenska (IS) (83.29 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Gaeilge (GA) (83.57 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View italiano (IT) (82.29 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View latviešu valoda (LV) (94.29 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View lietuvių kalba (LT) (94.03 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View magyar (HU) (94.15 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Malti (MT) (95.95 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Nederlands (NL) (82.05 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View norsk (NO) (82 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View polski (PL) (95.62 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View português (PT) (83.01 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View română (RO) (94.17 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View slovenčina (SK) (94.08 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View slovenščina (SL) (82.27 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Suomi (FI) (81.54 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View svenska (SV) (82.05 KB - PDF) First published: 16/04/2021 Last updated: 14/03/2025 View Product details Name of medicine Prevexxion RN Active substance Live recombinant Marek’s disease (MD) virus, serotype 1, strain RN1250 International non-proprietary name (INN) or common name Marek's disease vaccine (live recombinant) Pharmacotherapeutic groupImmunologicals for avesDomestic fowlAvian herpes virus (marek's disease) Authorisation details EMA product number EMEA/V/C/005058 Assessment history Expand section Collapse section Changes since initial authorisation of medicine Prevexxion RN : EPAR - Procedural steps taken and scientific information after authorisation English (EN) (81.94 KB - PDF)First published: 06/05/2021 Last updated: 14/03/2025 View Initial marketing authorisation documents Prevexxion RN : EPAR - Public assessment reportAdopted Reference Number: EMA/321289/2020 English (EN) (81.49 KB - PDF)First published: 16/04/2021 Last updated: 14/03/2025 View CVMP summary of positive opinion for Prevexxion RNAdopted Reference Number: EMA/CVMP/240890/2020 English (EN) (141 KB - PDF)First published: 25/05/2020 View News on Prevexxion RN Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 3-5 December 202406/12/2024 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 13-15 June 202316/06/2023 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 18-20 April 202321/04/2023 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 6-8 September 202209/09/2022 Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 5-7 October 202108/10/2021 Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 18-20 May 202025/05/2020 Topics Medicines Vaccines This page was last updated on 14/03/2025 Share this page